Get App

Sanofi and Translate Bio start clinical trial for mRNA flu vaccine

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
  • Published On Jun 22, 2021 at 12:58 PM IST
Paris: French healthcare group Sanofi and U.S. partner Translate Bio have started a Phase I clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza, the companies said on Tuesday.

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.

Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at risk, such as older adults and younger children, the companies added.
  • Published On Jun 22, 2021 at 12:58 PM IST

Comments

comment
What are your thoughts?
Comment Now Read Comment (1)

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!